BiotechTube

AZD2014

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurofibromatosis 2

Conditions

Neurofibromatosis 2, Meningioma

Trial Timeline

Aug 31, 2016 → Oct 1, 2020

NCT ID
NCT02831257

About AZD2014

AZD2014 is a phase 2 stage product being developed by AstraZeneca for Neurofibromatosis 2. The current trial status is completed. This product is registered under clinical trial identifier NCT02831257. Target conditions include Neurofibromatosis 2, Meningioma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (6)

NCT IDPhaseStatus
NCT03071874Phase 2UNKNOWN
NCT02619864Phase 1Completed
NCT02831257Phase 2Completed
NCT02398747Phase 1Completed
NCT02064608Phase 1Completed
NCT01026402Phase 1Completed

Competing Products

20 competing products in Neurofibromatosis 2

See all competitors
ProductCompanyStageHype Score
SelumetinibAstraZenecaPhase 2
52
SelumetinibAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1
33
Selumetinib + PlaceboAstraZenecaPhase 2
52
Treatment A + Treatment B + Treatment C + Treatment D + AcetaminophenAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1/2
41
SelumetinibAstraZenecaPhase 1
33
Selumetinib granule formulation + Selumetinib capsule formulationAstraZenecaPhase 1/2
41
SelumetinibAstraZenecaPhase 3
77
Everolimus (RAD001) , Afinitor®NovartisPhase 2
52
RAD001: EverolimusNovartisPhase 2
52
RAD001, everolimusNovartisPhase 2
52
TasignaNovartisPhase 1
33
TrametinibNovartisPhase 2
52
Everolimus (RAD001)NovartisPhase 2
52
Sutent®/SunitinibPfizerPhase 2
51
Sorafenib (Nexavar)BayerPhase 2
49
PTC299United TherapeuticsPhase 2
49
REC-2282 + PlaceboRecursion PharmaceuticalsPhase 2/3
60
BinimetinibPacific BiosciencesPhase 2
44

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85